The presence of the alternative allele has been previously associated with increased ovarian toxicity in breast cancer survivors receiving cyclophosphamide as part of the treatment regimen [19] and in vitro with increased CYP3A4 expression [37,38]. The gene discussed is CYP3A4; the disease is breast cancer.